Well-rounded portfolios leading to strong Q318 for Soft Tissue Fixation

SmartTRAK reports that the continued rounding out of portfolios is leading to some commoditization in the market, but also allowing companies to capitalize on the strength of their sales forces in new portions of the Sports Medicine Market. High single and double-digit growth reported...

Among the many topics covered in the Q318 Soft Tissue Fixation Market Recap are:

SUTUREGARD is on a mission to close more wounds simply and safely

SmartTRAK Spotlights SUTUREGARD medical, a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion.

Company Overview

Founded in 2015 and based in Portland, Oregon, SUTUREGARD™ Medical, Inc. is a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion. For skin cancer surgeons (Mohs Surgeons), SUTUREGARD’s initial target market, the SUTUREGARD™ device allows closure of wounds using tissue expansion instead of relying on flaps, grafts, or second intent healing. This is particularly useful for scalp and lower leg closures. For some skin cancer surgeons, this will add greater efficiency to their day. For other skin cancer surgeons, this will retain closures in their practice that they would have otherwise sent to other specialists.

The Company founders — a Corvallis, Oregon-based skin cancer (Moh’s) surgeon and his Ph.D. nurse business partner — designed the SUTUREGARD device. The Company invested three years conducting bench research, pre-clinical studies, and customer discovery prior to completion of a successful human use study in 2018.

“SUTUREGARD Medical launched the SUTUREGARD device in November, 2018 at the Fundamentals of Mohs Surgery Conference and the product was enthusiastically received by surgeons.”   Dan Ladizinsky, MD, CEO of SUTUREGARD Medical.

SmartTRAK identifies trends to watch in spinal cord stimulation 

With the start of a new year, it's time to look back at 2018 and identify continuing and emerging trends in the market for Spinal Cord Stimulation (SCS) that are likely to shape the landscape in 2019 and beyond.

So what’s on the horizon? Anne Staylor, SmartTRAK Managing Editor, gives her predictions for the top technology and market trends to watch.

Among the many interesting and informative topics covered in the article are:

In an interview with SmartTRAK, B. Todd Sitzman, MD, MPH, President of the North American Neuromodulation Society (NANS), provides a preview of the educational opportunities, key research and emerging technologies that will be at the NANS 22^nd Annual meeting to be held January 17-20, 2019 in Las Vegas, NV. Dr. Sitzman expects NANS 2019 to be the biggest meeting yet for the premier neuromodulation society, with up to 3000 attendees and 300+ abstracts presented, organized around the theme of “The Science Behind Successful Outcomes.”

To find out more about the meeting, click on the video below to listen to SmartTRAK’s interview with Dr. Sitzman, recorded via Skype from his office in Hattiesburg, Mississippi (11:53 minutes). 

Robotics Contributing to Above Market Growth Through Implant Pull-Through

Robotics continued to be a hot topic in orthopedics in Q318 with some companies and surgeons projecting that robotics will become standard-of-care in orthopedic procedures in the next 3-5 years...

Among the many interesting topics covered in SmartTRAK's Q318 CAS Ortho Market Recap are:

Spine robotics was a hot topic throughout Q318, culminating at the NASS meeting in September.

SmartTRAK reports that with increasing adoption of spine robotic systems and potential expanded indications beyond pedicle screw placement on the horizon, market leader Medtronic believes that robotics will expand from ~5% of procedures in the US today to reach up to...

Among the many interesting topics covered in SmartTRAK's Q318 CAS Spine Market Recap are:

Tough comps, supply disruption and the ever-present pricing pressure impacts growth

SmartTRAK reports that the WW Trauma Market experienced a downturn in Q3, posting only +1.1% (reported) growth. The US Market was up +2.0% YoY, but is down sequentially compared to last quarter’s +5.0% gains...

Among the many topics covered in SmartTRAK's Q318 Trauma Market Recap are:

The US Surgical Matrices Market continued to advance in Q318, up +10.3% YoY, fueled by continued rapid adoption of allograft breast matrices and the resurgence of synthetic hernia matrices.

According to BioMedGPS’  SmartTRAK Financial Dashboard, in Q318, the US Surgical Matrices Market grew +10.3% YoY. The allograft breast matrices and biosynthetic hernia matrices segments outpaced overall market growth, as both posted...

Among the many interesting topics covered in the Q318 US Surgical Matrices Market Recap are:

Growth continues for another quarter as market leaders gain more share.

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market grew +4.3% YoY.

Among the many topics covered in the Q318 Infection Prevention Market Recap are: